Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Retained Earnings (2020 - 2025)

Arcutis Biotherapeutics has reported Retained Earnings over the past 6 years, most recently at -$1.1 billion for Q4 2025.

  • Quarterly results put Retained Earnings at -$1.1 billion for Q4 2025, down 1.44% from a year ago — trailing twelve months through Dec 2025 was -$1.1 billion (down 1.44% YoY), and the annual figure for FY2025 was -$1.1 billion, down 1.44%.
  • Retained Earnings for Q4 2025 was -$1.1 billion at Arcutis Biotherapeutics, up from -$1.2 billion in the prior quarter.
  • Over the last five years, Retained Earnings for ARQT hit a ceiling of -$36000.0 in Q2 2021 and a floor of -$1.2 billion in Q2 2025.
  • Median Retained Earnings over the past 5 years was -$683.8 million (2022), compared with a mean of -$598.7 million.
  • Biggest five-year swings in Retained Earnings: crashed 1499900.0% in 2022 and later soared 99.98% in 2024.
  • Arcutis Biotherapeutics' Retained Earnings stood at -$255000.0 in 2021, then crashed by 282174.51% to -$719.8 million in 2022, then crashed by 36.41% to -$981.9 million in 2023, then dropped by 14.26% to -$1.1 billion in 2024, then decreased by 1.44% to -$1.1 billion in 2025.
  • The last three reported values for Retained Earnings were -$1.1 billion (Q4 2025), -$1.2 billion (Q3 2025), and -$1.2 billion (Q2 2025) per Business Quant data.